Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNTH-2403 Imaging in Advanced Solid Tumors
NCT07272642Phase 1Not yet recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LNTH-2403 in colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 1 more, sponsored by Radiopharm Theranostics. Primary endpoint: Safety and tolerability of a single dose of LNTH-2403 at 90 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LNTH-2403
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07272642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272642.